HebeBio Secures Strategic Investment to Accelerate Development of GLP-1 Obesity Therapy

Singapore – November 1, 2024 – HebeBio is pleased to announce the completion of its Pre-A financing round, welcoming two strategic investors aligned with the company’s growth plans. This milestone will accelerate the advancement of HebeBio’s promising Dual GLP-1 receptor agonist (GLP-1 RA) asset. 

With its unique solution for addressing challenges in obesity therapy, HebeBio’s optimized Bispecific GLP-1 RA candidate is progressing toward pre-clinical proof of concept (PoC) testing. Led by an experienced team with a robust background in GLP-1 discovery and translational medicine, HebeBio is leveraging the latest in clinical development expertise to maximize the therapeutic potential of its candidate. The asset is currently in late-stage optimization, with pre-clinical PoC anticipated for 2025, paving the way for potential early exit opportunities in 2027. 

Learn more about HebeBio’s mission and latest advancements in obesity treatment by exploring our Solutions and News sections.